The Filing Desk

Tango Therapeutics

TNGX · Nasdaq · Health Care · Financials, fiscal 2020 to 2025

TNGX · Last close · November 13, 2026
$25.50
Value Tango Therapeutics yourself

Tango Therapeutics' revenue rose 48.3% to $62 million in fiscal 2025. Its operating margin was −178.4%, up from −346.1% a year earlier. Free cash flow was −$140 million. The diluted share count rose 6.3%.

TANGO THERAPEUTICS, INC. Latest fiscal year ended December 31, 2025 10-K filed March 5, 2026 · 0001193125-26-092518 Updated
Revenue
$62M
48.3%
Operating margin
−178.4%
167.7 pts
Net income
−$102M
 
Free cash flow
−$140M
 
Return on equity
−37.2%
20.4 pts
Market cap
$4.4B
Nov 13 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What Tango Therapeutics does

Tango Therapeutics is a drug developer focused on cancer. It looks for medicines that work against cancer cells with specific genetic changes while sparing normal cells. It has no products approved for sale and has not earned revenue from product sales.

Its work is centered on two experimental drugs that block a protein called PRMT5 in cancers that lack a gene called MTAP. Vopimetostat (TNG462) is aimed at cancers outside the brain and spinal cord, both alone and combined with drugs that block RAS, a common cancer-driving protein. TNG456 is designed to reach the brain and is aimed at brain cancers, including glioblastoma. In October 2025 the company reported data from an ongoing Phase 1/2 trial of vopimetostat, and it plans to start a pivotal trial in second-line pancreatic cancer in 2026.

Tango pays for its research by raising money from investors and through partnerships, not by selling medicines. It runs combination trials with drugs from Revolution Medicines, and in March 2026 it agreed to test vopimetostat alongside a drug from Erasca. It also has a discovery program that looks for new targets. At the end of 2025 it had 137 full-time employees, most of them in research and development.

Its biggest risks, as it describes them

  • It has no approved products, has never earned product revenue, and may never become profitable.
  • It has lost money since it began and will need to raise a lot more funding, which could dilute shareholders.
  • Its drugs may fail in clinical trials, show safety problems, or be delayed or not approved.
  • Early results may not hold up in later trials, and trial data it announces can change.
  • Competitors may develop rival cancer treatments first, and its approach is new and unproven.
From Tango Therapeutics's annual report on Form 10-K, filed March 5, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

Tango Therapeutics lost money in fiscal 2025: a net loss of $102 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments485366337258343
Debt incl. finance leases—————
Net debt (negative means net cash)—————
Net debt to EBITDA—————
Debt to equity—————
Interest coverage—————
Current ratio12.1x6.8x7.5x7.0x16.3x
Quick ratio12.1x6.8x7.5x7.0x16.3x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Tango Therapeutics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

Over the 12 months between November 14, 2025 and November 13, 2026, no insider bought Tango Therapeutics shares on the open market, and 4 insiders sold $7.2 million, $6.4 million of it under trading plans set up in advance.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Nov 11, 2026Adam CrystalPresident, R&DSold plan5,000$25.00$125,000Form 4
Sep 22, 2026Jessica NewcombPrincipal Accounting OfficerSold plan8,200$24.22$198,615Form 4
Sep 1, 2026Adam CrystalPresident, R&DSold plan27,000$22.37$603,990Form 4
Aug 3, 2026Adam CrystalPresident, R&DSold plan27,000$27.24$735,500Form 4
Jul 1, 2026Adam CrystalPresident, R&DSold plan27,000$29.59$798,888Form 4
Jun 1, 2026Adam CrystalPresident, R&DSold plan27,000$22.88$617,647Form 4
May 1, 2026Adam CrystalPresident, R&DSold plan27,000$21.22$573,021Form 4
Apr 15, 2026Adam CrystalPresident, R&DSold plan38,460$25.00$961,500Form 4
Apr 1, 2026Adam CrystalPresident, R&DSold plan27,000$21.20$572,400Form 4
Mar 25, 2026Adam CrystalPresident, R&DSold plan12,000$20.11$241,320Form 4
Mar 5, 2026Adam CrystalPresident, R&DSold plan20,251$15.00$303,765Form 4
Feb 25, 2026Adam CrystalPresident, R&DSold plan54,345$12.77$693,986Form 4
The latest 12 of 15 trades. Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score———
Rule of 40−280.2%−299.2%−176.0%
Altman Z''1.76−1.745.58
Accruals ratio3.9%0.3%10.4%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailFailFail
Return on assets roseFailFailPass
Cash from operations exceeds net incomeFailFailFail
Debt fell relative to assets———
Current ratio rosePassFailPass
Share count didn't riseFailFailFail
Gross margin rose———
Revenue rose relative to assetsPassPassPass
F-score———
Companies that report no gross profit are scored on the other eight.

Compare

Put Tango Therapeutics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Tango TherapeuticsFY2548.3%−178.4%−224.3%———
Nuvation BioFY25699.0%−338.7%−288.4%———Compare
Kura OncologyFY2525.2%−449.9%−104.8%——3Compare
Nektar TherapeuticsFY25−43.9%−253.7%−377.8%——2Compare
Viridian TherapeuticsFY2523,359.9%−512.9%−390.8%———Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

6 years of figures

Fiscal yearFY20FY21FY22FY23FY24FY25
Income statement
Revenue83725364262
Revenue growth—383.8%−32.9%46.9%15.2%48.3%
Gross profit——————
Research and development5078106115144132
Operating income−52−58−111−114−146−111
Net income−52−58−108−102−130−102
Diluted EPS (US$)−1.63−0.94−1.23−1.08−1.19−0.87
Diluted shares (millions)32628895109116
Cash flow
Cash from operations70−60−109−118−132−139
Capital expenditure128211
Free cash flow69−61−117−120−132−140
Dividends paid000000
Share buybacks000000
Acquisitions000000
Stock-based compensation2814192926
Balance sheet at fiscal year end
Cash and short-term investments190485366337258343
Debt incl. finance leases——————
Total assets207500436403316399
Total liabilities16915518715011752
Shareholders' equity39345250253200346
Margins and ratios
Gross margin——————
Operating margin−681.8%−157.1%−446.8%−312.6%−346.1%−178.4%
Net margin−678.8%−157.2%−435.1%−278.5%−309.7%−162.8%
Free cash flow margin900.8%−165.7%−469.7%−327.2%−314.4%−224.3%
Rule of 40 (growth + FCF margin)—218.2%−502.6%−280.2%−299.2%−176.0%
Return on capital——————
Return on equity—−30.4%−36.4%−40.5%−57.6%−37.2%
Return on assets—−16.5%−23.1%−24.2%−36.2%−28.4%
Net debt to EBITDA——————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Tango Therapeutics' Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Tango Therapeutics.